- Home
- BSBK vs GNLX Comparison
BSBK vs GNLX Comparison
Compare BSBK & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSBK | GNLX |
|---|---|---|
| Founded | 1893 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.4M | 113.6M |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BSBK | GNLX |
|---|---|---|
| Price | $8.41 | $2.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 12.7K | ★ 160.7K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 200.00 | 9.47 |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $141.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.94 | $2.29 |
| 52 Week High | $9.49 | $8.54 |
Technical Indicators
Market Signals| Indicator | BSBK | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 50.15 |
| Support Level | $8.17 | $2.39 |
| Resistance Level | $8.63 | $2.97 |
| Average True Range (ATR) | 0.20 | 0.24 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 52.38 | 39.86 |
Price Performance
Historical ComparisonAbout BSBK Bogota Financial Corp.
Bogota Financial Corp is a New Jersey-based bank. It offers personal and business banking services such as savings, certificates of deposits, online banking, loans, and many more. The Bank generally grants residential, commercial, and consumer loans to, and accepts deposits from, customers in New Jersey. The Company operates one reportable segment of business, retail banking. Through its community banking segment, the Company provides a broad range of retail and commercial banking services.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.